(Page 2 of 2)
Oxford Nanopore as part of a deal to sell Oxford’s DNA sequencing machines when they’re ready for market.
—Waltham, MA-based Syndax Pharmaceuticals, which is developing anti-tumor drugs based on the scientific research of the Salk Institute’s Ron Evans, has raised $9 million of a targeted $16 million round, according to a recent SEC filing. The offering comprises equity, options, and warrants, according to the filing. Syndax, which was founded in 2005, raised $40 million in 2007.
—Billionaire investor Carl Icahn and his affiliated investment firms have filed the paperwork needed to nominate three people to the board of Biogen Idec (NASDAQ:BIIB), the Cambridge, MA-based biotech that maintains a significant presence in San Diego. Icahn has nominated Thomas Deuel, a former board member at Imclone and a cancer researcher at The Scripps Research Institute in San Diego. Also nominated is MIT biologist Richard Young and Eric Rowinsky, the former chief medical officer at Imclone.
—Just in time for next week’s Bio-Based Chemicals Summit in San Diego, Allylix has raised $6 million in new equity capital, according to a recent filing with the SEC. San Diego-based Allyx, which was founded in 2002, uses genetically engineered yeast to develop specialty products based on terpenes, which are produced in minute quantities in green plants.